|
Drug
|
Dose
|
Time (weeks)
|
ADAS-Cog Effect
|
Drug
|
Dose
|
Time (weeks)
|
ADAS-Cog Effect
|
|---|
|
Placebo
|
0
|
12
|
0.27
|
Galantamine
|
16
|
26
|
-1.10
|
|
Placebo
|
0
|
26
|
1.87
|
Galantamine
|
16
|
52
|
1.49
|
|
Placebo
|
0
|
52
|
5.07
|
Galantamine
|
24
|
12
|
-1.96
|
|
Placebo
|
0
|
78
|
7.10
|
Galantamine
|
24
|
26
|
-1.10
|
|
Donepezil
|
5
|
12
|
-1.77
|
Galantamine
|
24
|
52
|
1.49
|
|
Donepezil
|
5
|
26
|
-0.27
|
Rivastigmine
|
6
|
12
|
-0.66
|
|
Donepezil
|
5
|
52
|
2.87
|
Rivastigmine
|
6
|
26
|
0.70
|
|
Donepezil
|
10
|
12
|
-2.12
|
Rivastigmine
|
6
|
52
|
3.71
|
|
Donepezil
|
10
|
26
|
-0.64
|
Rivastigmine
|
12
|
12
|
-1.82
|
|
Donepezil
|
10
|
52
|
2.48
|
Rivastigmine
|
12
|
26
|
-0.77
|
|
Galantamine
|
8
|
12
|
-1.77
|
Rivastigmine
|
12
|
52
|
2.01
|
|
Galantamine
|
8
|
26
|
-0.95
|
SB-742457
|
5
|
26
|
-0.22
|
|
Galantamine
|
8
|
52
|
1.29
|
SB-742457
|
15
|
26
|
-0.66
|
|
Galantamine
|
16
|
12
|
-1.96
|
SB-742457
|
35
|
26
|
-1.12
|
- Clinical ADAS-Cog changes for different drugs, doses and time points, used in the calibration of the AD network model. The values are derived from the population kinetic model based upon a meta-analysis and other reports on placebo and 5-HT6 antagonists.
